{"componentChunkName":"component---src-templates-lie-template-tsx","path":"/lie/30701/","result":{"pageContext":{"id":"30701","location":"Remarks","claim":"“The unprecedented reforms we're completing today are the direct result of the historic drug pricing executive orders I signed in July. Statutorily, we had to go through a very long process, and we got it done. I was very proud to have gotten this done.”","analysis":"Actually, the administration took a shortcut. Trump announced Health and Human Services had issued an “interim final rule,\" meaning the Trump administration skipped the normal rulemaking process, which requires weeks for public comment. That could make it difficult for the Biden administration to defend the most-favored-nation policy in court if the pharmaceutical industry sues over the rule. Indeed, in late December a federal judge issued a nationwide injunction that prevented the Centers for Medicare and Medicaid Services, or CMS, from carrying out the so-called “most favored nations” rule as scheduled on Jan. 1. The judge wrote in her temporary order that CMS had failed to follow required procedures for notice and comment before imposing such sweeping changes.","pinocchios":"","category":"Health care","repeated_ids":"","repeated_count":"0","date":"11/20/2020","portfolio":"lie"}},"staticQueryHashes":["3649515864"]}